Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands

Hein J. Boot*, Iris Wallenburg, Hester E. de Melker, Marie José M Mangen, Annette A M Gerritsen, Nicoline A. van der Maas, Johannes Berkhof, Chris J L M Meijer, Tjeerd G. Kimman

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

A persistent infection with human papillomavirus (HPV) is a prerequisite for the development of cervical cancer. Clinical trials with HPV-vaccines have been very successful in preventing persistent HPV16/18 infections, the two most oncogenic HPV-genotypes. We assessed the introduction of universal HPV-vaccination for preadolescent girls in the Dutch National Immunization Programme. Long-term vaccine efficacy, the need and extent of a catch-up programme for young women, and the impact of vaccination on the cervical cancer screening programme are major unresolved issues. Preliminary conservative estimates (80% vaccine efficacy and no effects on the screening programme, transmission rate, non-cervical cancer incidence, and cross protection) predict an acceptable cost-effectiveness ratio for universal vaccination of preadolescent girls.

Original languageEnglish
Pages (from-to)6245-6256
Number of pages12
JournalVaccine
Volume25
Issue number33
DOIs
Publication statusPublished - 14 Aug 2007

Cite this

Boot, H. J., Wallenburg, I., de Melker, H. E., Mangen, M. J. M., Gerritsen, A. A. M., van der Maas, N. A., ... Kimman, T. G. (2007). Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands. Vaccine, 25(33), 6245-6256. https://doi.org/10.1016/j.vaccine.2007.05.061